ScreenerHero

RANI Rani Therapeutics Holdings, Inc.

NAS · US · Healthcare · Biotechnology · ranitherapeutics.com
0.8121USD-2.02%Mkt Cap: 114.12M $P/E: —

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap114.12M USD
Enterprise Value54.57M USD
Revenue (TTM)4.88M USD
Gross Profit4.88M USD
Net Income (TTM)-29.67M USD
Revenue/Share0.04 USD
Last Price0.8121 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.36
PEG—
EV/EBITDA-1.69
EV/Revenue11.19
P/S23.88
P/B2.37
EPS (TTM)-0.15
EPS (Forward)-0.19
52W Range
0.445011% of range3.870
52W High3.870 USD
52W Low0.4450 USD
Profitability
Gross Margin100.00%
Oper. Margin-516.86%
EBITDA Margin0.00%
Profit Margin-1817.09%
ROE-89.89%
ROA-50.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.71M USD
CapEx (TTM)88.00K USD
FCF Margin-181.96%
FCF Yield-7.78%
Net Debt-49.84M USD
Net Debt/EBITDA1.55
Balance Sheet
Debt/Equity0.13
Current Ratio5.31
Quick Ratio5.23
Book Value/Sh0.35 USD
Cash/Share0.46 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.200 USD
Upside (mean)+786.6%
Target Range5.000 USD – 11.00 USD
5.000+786.6% to mean11.00
# Analysts5
Ownership
Shares Out.115.42M
Float82.32M
Insiders4.91%
Institutions46.80%
Short Interest
Short Ratio11.0d
Short % Float6.33%
Short % Out.6.17%
Shares Short7.12M
Short (prev mo.)8.16M
Technical
SMA 500.8193 (-0.9%)
SMA 2001.003 (-19.1%)
Beta0.71
S&P 52W Chg16.45%
Avg Vol (30d)565.33K
Avg Vol (10d)527.25K
Technical Indicators
RSI (14)50.6
MACD-0.0056
MACD Signal-0.0070
MACD Hist.+0.0013
BB Upper0.8830 USD
BB Middle0.8102 USD
BB Lower0.7374 USD
BB Width17.97%
ATR (14)0.0501 USD
Vol Ratio (20d)0.44x